Ruxolitinib for the Treatment of T-Cell Large Granular Lymphocytic Leukemia
Status:
Not yet recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
This phase II trial tests whether ruxolitinib works to shrink tumors in patients with T-cell
large granular lymphocyte leukemia. Ruxolitinib may stop the growth of cancer cells by
blocking some of the enzymes needed for cell growth.